Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma.

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Elranatamab is an approved bispecific antibody for relapsed or refractory multiple myeloma (RRMM).
• Understanding the relationship between elranatamab exposure and safety is crucial for optimizing treatment.
• Four clinical studies (MagnetisMM-1, 2, 3, and 9) provided data for this analysis.

Purpose of the Study:

• To analyze the exposure-safety relationship of elranatamab in patients with RRMM.
• To evaluate the association between elranatamab exposure and key safety endpoints.
• To explore the link between elranatamab exposure and dose modifications.

Main Methods:

• Exposure-safety analysis using data from four clinical studies.
• Evaluation of safety endpoints including grade ≥3 infections, neutropenia, anemia, and thrombocytopenia.
• Assessment of the relationship between elranatamab exposure and dose interruptions/discontinuations.

Main Results:

• No statistically significant relationship was found between elranatamab exposure and the incidence of evaluated safety events.
• A flat exposure-safety profile was observed, indicating similar risks across the efficacious dose range.
• The 76-mg once-weekly (QW) regimen showed comparable safety event probabilities to lower doses.

Conclusions:

• The findings support the use of the full 76 mg QW dose of elranatamab.
• Lowering the dose is unlikely to significantly mitigate the risk of adverse events.
• Temporary dose interruption is a preferred strategy for managing elranatamab adverse drug reactions over dose reduction.